



AKT2 Positive Control

(Human, a.a.148-481, recombinant protein expressed in Sf9 cells)
Cat# CY-E1168-2

Lot No.
For 200 Assays
5 units (6.25 m units/ μ L)

Supplied with 10X BSA (100 μ g/mL x 0.25 mL) to make Enzyme Dilution Buffer.

Product Description: Constitutive active form of human AKT2, in which there is one mutation S474D, containing an N-terminal GST tag and a C-terminal His tag, is produced by co-infection with PDK-1, expressing recombinant baculovirus into Sf9 cells, and purified by using GSH agarose chromatography. The AKT2 Positive Control is designed to use for CycLex AKT/PKB Kinase Assay/Inhibitor Screening Kit (Cat# CY-1168). The AKT2 Positive Control should be added to the well at 25 m units/well. Unused AKT2 Positive Control should be stored at -70°C.

Product Size: 5 units/800 μ L

Formulation: Supplied frozen in a buffer containing 20 mM Hepes-KOH (pH 7.5), 1 % BSA, 1 mM EDTA, 1 mM DTT, 50 mM NaCl, 0.03 % Brij35 and 50 % glycerol.

Dilution: The AKT2 Positive Control should be diluted with Enzyme Dilution Buffer* to avoid inactivating the enzyme activity in low protein concentration condition.

* Enzyme Dilution Buffer: Mix 9-parts of Kinase Buffer of CycLex AKT/PKB Kinase Assay/Inhibitor Screening Kit (Cat# CY-1168) and 1-part of 10X BSA (100 μ g/mL)

Source: Human AKT2, 148-481, S474D, containing an N-terminal GST tag and a C-terminal His tag, expressed in Sf9 cells.

Molecular Weight: 92 kDa doublet bands by SDS-PAGE analysis.

Purity: > 90% pure as determined by SDS-PAGE analysis.

Substrates: AKT2 phosphorylates a number of substrates, including GSK-3 α , Apaf-1, hTERT, Bad and MBP.

Inhibitors: AKT2 specific inhibitor has not been discovered yet.

Unit Definition: One unit is defined as the amount of kinase required to incorporate 1nmol of phosphate into the GST-Bad per minute at 30°C.

Assay Conditions: Assay activity of AKT2 in a 50 μ L reaction containing 20 mM Hepes KOH (pH 7.5), 5 mM MgCl₂, 1 mM DTT, 100 μ M [γ -³²P] ATP (1 μ Ci), and 4 μ g of GST-Bad fusion protein. Start the reaction by adding 10 μ L of the enzyme, diluted 50-fold in a buffer containing 20 mM Hepes KOH (pH 7.5), 1 mM DTT, 0.03 % Brij35. Incubate for 30 minutes at 30°C. Terminate the reaction by adding 600 μ L of cold 10 % TCA solution containing 0.2 % Sodium pyrophosphate and stand on ice for 15 min. Filtrate acid insoluble material through GFC filters (Whatman Inc.), wash 4



AKT2 Positive Control

Product Data Sheet

For Research Use Only, Not for use in diagnostic procedures



times with 1 % TCA and rinse filters with ethanol. Dry filters and count in a liquid scintillation counter.

Storage and Stability: Stable for 12 months at -70°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot enzyme to avoid repeated freezing and thawing.

References:

1. Staal, S. P. *Proc. Nat. Acad. Sci.* 84, 5034-5037, 1987.
2. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA. *J Biol Chem.* 272, 31515-24, 1997
3. Meier, R., Alessi, D. R., Cron, P., Andjelkovic, M. and Hemmings, B. A. *J. Biol. Chem.* 272, 30491–30497, 1997
4. Cross, D. A.E., Alessi, D. R., Cohen, P., Andjelković, M., and Hemmings, B. A. *Nature* 378, 785-789, 1995
5. Kohn, A. D., Summers, S. A., Birnbaum, M. J., and Roth, R. A. *J. Biol. Chem.* 271, 31372-31378, 1996
6. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. *Science* 275, 661-665, 1997
7. Cheng, J.Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., and Testa, J. R. *Proc. Nat. Acad. Sci.* 89, 9267-9271, 1992
8. Bellacosa, A. et al. *Int. J. Cancer* 64, 280-285, 1995
9. Cheng, J.Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., and Testa, J. R. *Proc. Nat. Acad. Sci.* 93, 3636-3641, 1996
10. Vanhaesebroeck, B.; Alessi, D. R. *Biochem. J.* 346, 561-576, 2000. (Review)
11. Franke, T. F., Kaplan, D. R., and Cantley, L. C. *Cell* 88, 435-437, 1997 (Review)
12. Hemmings, B. A. *Science* 275, 628-630, 1997 (Review)

For more information, please visit our web site.

<https://ruo.mbl.co.jp/>

MANUFACTURED BY

MBL A JSR Life Sciences Company

MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.

URL: <https://ruo.mbl.co.jp>

E-mail: support@mbl.co.jp

CycLex/CircuLex products are supplied for research use only. CycLex/CircuLex products and components thereof may not be resold, modified for resale, or used to manufacture commercial products without prior written approval from MBL. To inquire about licensing for such commercial use, please contact us via email.